Kerendia is a prescription drug owned by Bayer Hlthcare. The active ingredient in Kerendia is finerenone. This drug was authorized for market use on July 9, 2021. Kerendia is available in tablet form and is administered orally. There is currently one patent for Kerendia, none of which have expired so far.
The generic version of Kerendia is expected to be released after April 12, 2029. This date corresponds with the expiration of the patent titled 'Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof', which is set to expire on April 12, 2029. Meanwhile, drug patent challenges against Kerendia can be filed from July 9, 2025.
Kerendia is used for the treatment of various medical conditions. The active ingredient, finerenone, plays a vital role in its effectiveness. finerenone is a nonsteroidal mineralocorticoid receptor antagonist that is primarily used in the treatment of chronic kidney disease associated with type 2 diabetes. It is known to reduce the risk of sustained decline in eGFR, end stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure.
Kerendia holds a single patent titled 'Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof'. This Kerendia generic patent is set to expire on April 12, 2029. Below are the details of the patent: